Compare ARVN & TRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARVN | TRNS |
|---|---|---|
| Founded | 2015 | 1964 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electrical Products |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.2M | 542.9M |
| IPO Year | 2018 | 1995 |
| Metric | ARVN | TRNS |
|---|---|---|
| Price | $8.04 | $92.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 19 | 1 |
| Target Price | $15.05 | ★ $116.00 |
| AVG Volume (30 Days) | ★ 680.3K | 198.8K |
| Earning Date | 05-04-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.84 | N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | $262,600,000.00 | ★ $331,877,000.00 |
| Revenue This Year | N/A | $21.75 |
| Revenue Next Year | N/A | $7.55 |
| P/E Ratio | ★ N/A | $157.25 |
| Revenue Growth | N/A | ★ 19.20 |
| 52 Week Low | $6.06 | $50.23 |
| 52 Week High | $14.22 | $94.76 |
| Indicator | ARVN | TRNS |
|---|---|---|
| Relative Strength Index (RSI) | 46.65 | 60.67 |
| Support Level | $7.35 | $68.27 |
| Resistance Level | $10.18 | $94.76 |
| Average True Range (ATR) | 0.41 | 4.11 |
| MACD | 0.17 | -0.34 |
| Stochastic Oscillator | 70.20 | 70.71 |
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Transcat Inc is involved in providing calibration and laboratory instrument services and the distribution of test, measurement, and control instrumentation. The product and services portfolio of the company consists of calibration instruments, dimensional measuring tools, Electrical test instruments, pressure measurement, and others. The firm has Service and Distribution operating segments. The company derives the majority of its revenues from the Service segment. The firm promotes and sells its products under brand names such as Extech, FLIR, Fluke, Keysight, Megger, and others.